Sugi Predict

Sugi Predict / Compounds / SCHEMBL6030746

SCHEMBL6030746

SCHEMBL6030746

CCCCCCCCOC(=O)Nc1sc(C(C)CC(C)(C)C)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 3/20 0.41
▸ CSNK2A1 P68400 3/20 0.41
▸ GRIN2C Q14957 1/20 0.38
▸ SMN1; SMN2 Q16637 6/20 0.38
▸ NPC1 O15118 5/20 0.38
▸ RAB9A P51151 5/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ EPHX1 P07099 1/20 0.36
▸ FAAH O00519 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029902 0.89 HSD17B10 (0.40) CSNK2A2CSNK2A1SMN1; SMN2NPC1RAB9A
SCHEMBL6030446 0.87 CSNK2A2 (0.46) CSNK2A2CSNK2A1SMN1; SMN2NPC1RAB9A
SCHEMBL6030754 0.79 CSNK2A2 (0.48) CSNK2A2CSNK2A1SMN1; SMN2NPC1RAB9A
SCHEMBL6031351 0.78 HSD17B10 (0.42) CSNK2A2CSNK2A1SMN1; SMN2NPC1RAB9A
SCHEMBL6031060 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1
SCHEMBL6031306 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1
SCHEMBL6031439 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1
SCHEMBL6031638 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1
SCHEMBL6030418 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1
SCHEMBL6031411 0.78 HSD17B10 (0.54) CSNK2A2CSNK2A1GRIN2CSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 — — US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 — — EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 — — EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 — — US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL CSNK2A2 1345/4885CSNK2A1 1181/4885GRIN2C 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.